Loading…

Acquired, Nonrandom Chromosomal Abnormalities Associated with the Development of Acute Promyelocytic Leukemia in Transgenic Mice

We previously generated a transgenic mouse model for acute promyelocytic leukemia (APL) by expressing the promyelocytic leukemia (PML)-retinoic acid receptor (RARα ) cDNA in early myeloid cells. This fusion protein causes a myeloproliferative disease in 100% of animals, but only 15-20% of the animal...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings of the National Academy of Sciences - PNAS 2000-11, Vol.97 (24), p.13306-13311
Main Authors: Zimonjic, Drazen B., Pollock, Jessica L., Westervelt, Peter, Popescu, Nicholas C., Ley, Timothy J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c498t-bf8517520363949adedd7b352153205592cdf51c28394ed52fd0c1439397f0013
cites cdi_FETCH-LOGICAL-c498t-bf8517520363949adedd7b352153205592cdf51c28394ed52fd0c1439397f0013
container_end_page 13311
container_issue 24
container_start_page 13306
container_title Proceedings of the National Academy of Sciences - PNAS
container_volume 97
creator Zimonjic, Drazen B.
Pollock, Jessica L.
Westervelt, Peter
Popescu, Nicholas C.
Ley, Timothy J.
description We previously generated a transgenic mouse model for acute promyelocytic leukemia (APL) by expressing the promyelocytic leukemia (PML)-retinoic acid receptor (RARα ) cDNA in early myeloid cells. This fusion protein causes a myeloproliferative disease in 100% of animals, but only 15-20% of the animals develop acute leukemia after a long latency period (6-13 months). PML-RARα is therefore necessary, but not sufficient, for APL development. The coexpression of a reciprocal form of the fusion, RARα -PML, increased the likelihood of APL development (55-60%), but did not shorten latency. Together, these results suggested that additional genetic events are required for the development of APL. We therefore evaluated the splenic tumor cells from 18 transgenic mice with APL for evidence of secondary genetic events, by using spectral karyotyping analysis. Interstitial or terminal deletions of the distal region of one copy of chromosome 2 [del(2)] were found in 1/5 tumors expressing PML-RARα , but in 11/13 tumors expressing both PML-RARα and RARα -PML (P < 0.05). Leukemic cells that contained a deletion on chromosome 2 often contained additional chromosomal gains (especially of 15), chromosomal losses (especially of 11 or X/Y), or were tetraploid (P≤ 0.001). These changes did not commonly occur in nontransgenic littermates, nor in aged transgenic mice that did not develop APL. These results suggest that expression of RARα -PML increases the likelihood of chromosome 2 deletions in APL cells. Deletion 2 appears to predispose APL cells to further chromosomal instability, which may lead to the acquisition of additional changes that provide an advantage to the transformed cells.
doi_str_mv 10.1073/pnas.97.24.13306
format article
fullrecord <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmed_primary_11087871</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>123697</jstor_id><sourcerecordid>123697</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-bf8517520363949adedd7b352153205592cdf51c28394ed52fd0c1439397f0013</originalsourceid><addsrcrecordid>eNp9kUtvEzEUhS0EoiGwR0ICrxALEvyYiW2pm1FaHlJ4LMracuw7jcvMOLU9hez46TgkULphZeue79xzpYPQU0rmlAj-ZjuYNFdizqo55Zws7qEJJYrOFpUi99GEECZmsmLVCXqU0hUhRNWSPEQnlBIppKAT9LOx16OP4F7jT2GIZnChx8tNDH1IoTcdbtZDiOXjs4eEm5SC9SaDw9993uC8AXwGN9CFbQ9DxqHFjR0z4C9lw66M7S57i1cwfoPeG-wHfFFC0iUMZfzRW3iMHrSmS_Dk-E7R17fnF8v3s9Xndx-WzWpmKyXzbN3KmoqaEb7gqlLGgXNizWtGa85IXStmXVtTy2SRwdWsdcTSiiuuREsI5VN0eti7Hdc9OFuujabT2-h7E3c6GK_vKoPf6Mtwo5lgJXWKXh7tMVyPkLLufbLQdWaAMCZNheBSVrKA5ADaGFKK0P6NoETvS9P70rQSmlX6d2nF8vzf024Nx5YK8OII7K1_5LsrXv2f0O3YdRl-5II-O6BXKYd4G8b4Qgn-CwOUt4s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17738848</pqid></control><display><type>article</type><title>Acquired, Nonrandom Chromosomal Abnormalities Associated with the Development of Acute Promyelocytic Leukemia in Transgenic Mice</title><source>NCBI_PubMed Central(免费)</source><source>JSTOR-E-Journals</source><creator>Zimonjic, Drazen B. ; Pollock, Jessica L. ; Westervelt, Peter ; Popescu, Nicholas C. ; Ley, Timothy J.</creator><creatorcontrib>Zimonjic, Drazen B. ; Pollock, Jessica L. ; Westervelt, Peter ; Popescu, Nicholas C. ; Ley, Timothy J.</creatorcontrib><description>We previously generated a transgenic mouse model for acute promyelocytic leukemia (APL) by expressing the promyelocytic leukemia (PML)-retinoic acid receptor (RARα ) cDNA in early myeloid cells. This fusion protein causes a myeloproliferative disease in 100% of animals, but only 15-20% of the animals develop acute leukemia after a long latency period (6-13 months). PML-RARα is therefore necessary, but not sufficient, for APL development. The coexpression of a reciprocal form of the fusion, RARα -PML, increased the likelihood of APL development (55-60%), but did not shorten latency. Together, these results suggested that additional genetic events are required for the development of APL. We therefore evaluated the splenic tumor cells from 18 transgenic mice with APL for evidence of secondary genetic events, by using spectral karyotyping analysis. Interstitial or terminal deletions of the distal region of one copy of chromosome 2 [del(2)] were found in 1/5 tumors expressing PML-RARα , but in 11/13 tumors expressing both PML-RARα and RARα -PML (P &lt; 0.05). Leukemic cells that contained a deletion on chromosome 2 often contained additional chromosomal gains (especially of 15), chromosomal losses (especially of 11 or X/Y), or were tetraploid (P≤ 0.001). These changes did not commonly occur in nontransgenic littermates, nor in aged transgenic mice that did not develop APL. These results suggest that expression of RARα -PML increases the likelihood of chromosome 2 deletions in APL cells. Deletion 2 appears to predispose APL cells to further chromosomal instability, which may lead to the acquisition of additional changes that provide an advantage to the transformed cells.</description><identifier>ISSN: 0027-8424</identifier><identifier>EISSN: 1091-6490</identifier><identifier>DOI: 10.1073/pnas.97.24.13306</identifier><identifier>PMID: 11087871</identifier><language>eng</language><publisher>United States: National Academy of Sciences of the United States of America</publisher><subject>Animals ; Biological Sciences ; Bone marrow cells ; chromosome 2 ; Chromosome Aberrations - genetics ; Chromosome Deletion ; Chromosome Disorders ; Chromosome Mapping ; Chromosomes ; Crosses, Genetic ; Female ; Genes ; Humans ; Karyotyping ; Leukemia ; Leukemia, Promyelocytic, Acute - genetics ; Leukemia, Promyelocytic, Acute - pathology ; Male ; Medical genetics ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Myeloid cells ; Neoplasm Proteins - genetics ; Neoplasm Staging ; Oncogene Proteins, Fusion - genetics ; Spleen cells ; Tetraploidy ; Transgenic animals ; Tumors</subject><ispartof>Proceedings of the National Academy of Sciences - PNAS, 2000-11, Vol.97 (24), p.13306-13311</ispartof><rights>Copyright 1993-2000 National Academy of Sciences of the United States of America</rights><rights>Copyright © 2000, The National Academy of Sciences 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c498t-bf8517520363949adedd7b352153205592cdf51c28394ed52fd0c1439397f0013</citedby><cites>FETCH-LOGICAL-c498t-bf8517520363949adedd7b352153205592cdf51c28394ed52fd0c1439397f0013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://www.pnas.org/content/97/24.cover.gif</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/123697$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/123697$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793,58238,58471</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11087871$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zimonjic, Drazen B.</creatorcontrib><creatorcontrib>Pollock, Jessica L.</creatorcontrib><creatorcontrib>Westervelt, Peter</creatorcontrib><creatorcontrib>Popescu, Nicholas C.</creatorcontrib><creatorcontrib>Ley, Timothy J.</creatorcontrib><title>Acquired, Nonrandom Chromosomal Abnormalities Associated with the Development of Acute Promyelocytic Leukemia in Transgenic Mice</title><title>Proceedings of the National Academy of Sciences - PNAS</title><addtitle>Proc Natl Acad Sci U S A</addtitle><description>We previously generated a transgenic mouse model for acute promyelocytic leukemia (APL) by expressing the promyelocytic leukemia (PML)-retinoic acid receptor (RARα ) cDNA in early myeloid cells. This fusion protein causes a myeloproliferative disease in 100% of animals, but only 15-20% of the animals develop acute leukemia after a long latency period (6-13 months). PML-RARα is therefore necessary, but not sufficient, for APL development. The coexpression of a reciprocal form of the fusion, RARα -PML, increased the likelihood of APL development (55-60%), but did not shorten latency. Together, these results suggested that additional genetic events are required for the development of APL. We therefore evaluated the splenic tumor cells from 18 transgenic mice with APL for evidence of secondary genetic events, by using spectral karyotyping analysis. Interstitial or terminal deletions of the distal region of one copy of chromosome 2 [del(2)] were found in 1/5 tumors expressing PML-RARα , but in 11/13 tumors expressing both PML-RARα and RARα -PML (P &lt; 0.05). Leukemic cells that contained a deletion on chromosome 2 often contained additional chromosomal gains (especially of 15), chromosomal losses (especially of 11 or X/Y), or were tetraploid (P≤ 0.001). These changes did not commonly occur in nontransgenic littermates, nor in aged transgenic mice that did not develop APL. These results suggest that expression of RARα -PML increases the likelihood of chromosome 2 deletions in APL cells. Deletion 2 appears to predispose APL cells to further chromosomal instability, which may lead to the acquisition of additional changes that provide an advantage to the transformed cells.</description><subject>Animals</subject><subject>Biological Sciences</subject><subject>Bone marrow cells</subject><subject>chromosome 2</subject><subject>Chromosome Aberrations - genetics</subject><subject>Chromosome Deletion</subject><subject>Chromosome Disorders</subject><subject>Chromosome Mapping</subject><subject>Chromosomes</subject><subject>Crosses, Genetic</subject><subject>Female</subject><subject>Genes</subject><subject>Humans</subject><subject>Karyotyping</subject><subject>Leukemia</subject><subject>Leukemia, Promyelocytic, Acute - genetics</subject><subject>Leukemia, Promyelocytic, Acute - pathology</subject><subject>Male</subject><subject>Medical genetics</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Transgenic</subject><subject>Myeloid cells</subject><subject>Neoplasm Proteins - genetics</subject><subject>Neoplasm Staging</subject><subject>Oncogene Proteins, Fusion - genetics</subject><subject>Spleen cells</subject><subject>Tetraploidy</subject><subject>Transgenic animals</subject><subject>Tumors</subject><issn>0027-8424</issn><issn>1091-6490</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNp9kUtvEzEUhS0EoiGwR0ICrxALEvyYiW2pm1FaHlJ4LMracuw7jcvMOLU9hez46TgkULphZeue79xzpYPQU0rmlAj-ZjuYNFdizqo55Zws7qEJJYrOFpUi99GEECZmsmLVCXqU0hUhRNWSPEQnlBIppKAT9LOx16OP4F7jT2GIZnChx8tNDH1IoTcdbtZDiOXjs4eEm5SC9SaDw9993uC8AXwGN9CFbQ9DxqHFjR0z4C9lw66M7S57i1cwfoPeG-wHfFFC0iUMZfzRW3iMHrSmS_Dk-E7R17fnF8v3s9Xndx-WzWpmKyXzbN3KmoqaEb7gqlLGgXNizWtGa85IXStmXVtTy2SRwdWsdcTSiiuuREsI5VN0eti7Hdc9OFuujabT2-h7E3c6GK_vKoPf6Mtwo5lgJXWKXh7tMVyPkLLufbLQdWaAMCZNheBSVrKA5ADaGFKK0P6NoETvS9P70rQSmlX6d2nF8vzf024Nx5YK8OII7K1_5LsrXv2f0O3YdRl-5II-O6BXKYd4G8b4Qgn-CwOUt4s</recordid><startdate>20001121</startdate><enddate>20001121</enddate><creator>Zimonjic, Drazen B.</creator><creator>Pollock, Jessica L.</creator><creator>Westervelt, Peter</creator><creator>Popescu, Nicholas C.</creator><creator>Ley, Timothy J.</creator><general>National Academy of Sciences of the United States of America</general><general>National Acad Sciences</general><general>The National Academy of Sciences</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope></search><sort><creationdate>20001121</creationdate><title>Acquired, Nonrandom Chromosomal Abnormalities Associated with the Development of Acute Promyelocytic Leukemia in Transgenic Mice</title><author>Zimonjic, Drazen B. ; Pollock, Jessica L. ; Westervelt, Peter ; Popescu, Nicholas C. ; Ley, Timothy J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-bf8517520363949adedd7b352153205592cdf51c28394ed52fd0c1439397f0013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Animals</topic><topic>Biological Sciences</topic><topic>Bone marrow cells</topic><topic>chromosome 2</topic><topic>Chromosome Aberrations - genetics</topic><topic>Chromosome Deletion</topic><topic>Chromosome Disorders</topic><topic>Chromosome Mapping</topic><topic>Chromosomes</topic><topic>Crosses, Genetic</topic><topic>Female</topic><topic>Genes</topic><topic>Humans</topic><topic>Karyotyping</topic><topic>Leukemia</topic><topic>Leukemia, Promyelocytic, Acute - genetics</topic><topic>Leukemia, Promyelocytic, Acute - pathology</topic><topic>Male</topic><topic>Medical genetics</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Transgenic</topic><topic>Myeloid cells</topic><topic>Neoplasm Proteins - genetics</topic><topic>Neoplasm Staging</topic><topic>Oncogene Proteins, Fusion - genetics</topic><topic>Spleen cells</topic><topic>Tetraploidy</topic><topic>Transgenic animals</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zimonjic, Drazen B.</creatorcontrib><creatorcontrib>Pollock, Jessica L.</creatorcontrib><creatorcontrib>Westervelt, Peter</creatorcontrib><creatorcontrib>Popescu, Nicholas C.</creatorcontrib><creatorcontrib>Ley, Timothy J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zimonjic, Drazen B.</au><au>Pollock, Jessica L.</au><au>Westervelt, Peter</au><au>Popescu, Nicholas C.</au><au>Ley, Timothy J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acquired, Nonrandom Chromosomal Abnormalities Associated with the Development of Acute Promyelocytic Leukemia in Transgenic Mice</atitle><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle><addtitle>Proc Natl Acad Sci U S A</addtitle><date>2000-11-21</date><risdate>2000</risdate><volume>97</volume><issue>24</issue><spage>13306</spage><epage>13311</epage><pages>13306-13311</pages><issn>0027-8424</issn><eissn>1091-6490</eissn><abstract>We previously generated a transgenic mouse model for acute promyelocytic leukemia (APL) by expressing the promyelocytic leukemia (PML)-retinoic acid receptor (RARα ) cDNA in early myeloid cells. This fusion protein causes a myeloproliferative disease in 100% of animals, but only 15-20% of the animals develop acute leukemia after a long latency period (6-13 months). PML-RARα is therefore necessary, but not sufficient, for APL development. The coexpression of a reciprocal form of the fusion, RARα -PML, increased the likelihood of APL development (55-60%), but did not shorten latency. Together, these results suggested that additional genetic events are required for the development of APL. We therefore evaluated the splenic tumor cells from 18 transgenic mice with APL for evidence of secondary genetic events, by using spectral karyotyping analysis. Interstitial or terminal deletions of the distal region of one copy of chromosome 2 [del(2)] were found in 1/5 tumors expressing PML-RARα , but in 11/13 tumors expressing both PML-RARα and RARα -PML (P &lt; 0.05). Leukemic cells that contained a deletion on chromosome 2 often contained additional chromosomal gains (especially of 15), chromosomal losses (especially of 11 or X/Y), or were tetraploid (P≤ 0.001). These changes did not commonly occur in nontransgenic littermates, nor in aged transgenic mice that did not develop APL. These results suggest that expression of RARα -PML increases the likelihood of chromosome 2 deletions in APL cells. Deletion 2 appears to predispose APL cells to further chromosomal instability, which may lead to the acquisition of additional changes that provide an advantage to the transformed cells.</abstract><cop>United States</cop><pub>National Academy of Sciences of the United States of America</pub><pmid>11087871</pmid><doi>10.1073/pnas.97.24.13306</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0027-8424
ispartof Proceedings of the National Academy of Sciences - PNAS, 2000-11, Vol.97 (24), p.13306-13311
issn 0027-8424
1091-6490
language eng
recordid cdi_pubmed_primary_11087871
source NCBI_PubMed Central(免费); JSTOR-E-Journals
subjects Animals
Biological Sciences
Bone marrow cells
chromosome 2
Chromosome Aberrations - genetics
Chromosome Deletion
Chromosome Disorders
Chromosome Mapping
Chromosomes
Crosses, Genetic
Female
Genes
Humans
Karyotyping
Leukemia
Leukemia, Promyelocytic, Acute - genetics
Leukemia, Promyelocytic, Acute - pathology
Male
Medical genetics
Mice
Mice, Inbred C57BL
Mice, Transgenic
Myeloid cells
Neoplasm Proteins - genetics
Neoplasm Staging
Oncogene Proteins, Fusion - genetics
Spleen cells
Tetraploidy
Transgenic animals
Tumors
title Acquired, Nonrandom Chromosomal Abnormalities Associated with the Development of Acute Promyelocytic Leukemia in Transgenic Mice
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T05%3A45%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acquired,%20Nonrandom%20Chromosomal%20Abnormalities%20Associated%20with%20the%20Development%20of%20Acute%20Promyelocytic%20Leukemia%20in%20Transgenic%20Mice&rft.jtitle=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20-%20PNAS&rft.au=Zimonjic,%20Drazen%20B.&rft.date=2000-11-21&rft.volume=97&rft.issue=24&rft.spage=13306&rft.epage=13311&rft.pages=13306-13311&rft.issn=0027-8424&rft.eissn=1091-6490&rft_id=info:doi/10.1073/pnas.97.24.13306&rft_dat=%3Cjstor_pubme%3E123697%3C/jstor_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c498t-bf8517520363949adedd7b352153205592cdf51c28394ed52fd0c1439397f0013%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17738848&rft_id=info:pmid/11087871&rft_jstor_id=123697&rfr_iscdi=true